272 related articles for article (PubMed ID: 18575628)
1. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.
Molokhia M; McKeigue P; Curcin V; Majeed A
PLoS One; 2008 Jun; 3(6):e2522. PubMed ID: 18575628
[TBL] [Abstract][Full Text] [Related]
2. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study.
Settergren J; Eiermann B; Mannheimer B
PLoS One; 2013; 8(8):e69545. PubMed ID: 23940522
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
4. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
5. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
[TBL] [Abstract][Full Text] [Related]
6. Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment.
Kang JH; Nguyen QN; Mutka J; Le QA
J Pharm Pract; 2017 Oct; 30(5):521-527. PubMed ID: 27798247
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.
Boonmuang P; Nathisuwan S; Chaiyakunapruk N; Suwankesawong W; Pokhagul P; Teerawattanapong N; Supsongserm P
Drug Saf; 2013 Sep; 36(9):779-87. PubMed ID: 23615756
[TBL] [Abstract][Full Text] [Related]
8. Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
Karimi S; Hough A; Beckey C; Parra D
J Manag Care Pharm; 2010 Sep; 16(7):472-81. PubMed ID: 20726676
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
10. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
Fung EC; Crook MA
Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
[TBL] [Abstract][Full Text] [Related]
11. Narrative review: statin-related myopathy.
Joy TR; Hegele RA
Ann Intern Med; 2009 Jun; 150(12):858-68. PubMed ID: 19528564
[TBL] [Abstract][Full Text] [Related]
12. Statin-Associated Bilateral Foot Myopathy.
Baggett MC; Nykamp D
J Pharm Pract; 2020 Dec; 33(6):899-902. PubMed ID: 31248326
[TBL] [Abstract][Full Text] [Related]
13. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy.
Keating AJ; Campbell KB; Guyton JR
Ann Pharmacother; 2013 Mar; 47(3):398-404. PubMed ID: 23482733
[TBL] [Abstract][Full Text] [Related]
14. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
[TBL] [Abstract][Full Text] [Related]
15. Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients.
Berta E; Harangi M; Zsíros N; Nagy EV; Paragh G; Bodor M
Pharmazie; 2014 Jun; 69(6):420-3. PubMed ID: 24974574
[TBL] [Abstract][Full Text] [Related]
16. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
[TBL] [Abstract][Full Text] [Related]
17. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
Nichols GA; Koro CE
Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
[TBL] [Abstract][Full Text] [Related]
18. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
[TBL] [Abstract][Full Text] [Related]
19. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q; Chen SQ; Ma LY; Hu K; Zhang Z; Mu GY; Xie QF; Zhang XD; Cui YM
Pharmacogenomics J; 2018 Dec; 18(6):721-729. PubMed ID: 30250148
[TBL] [Abstract][Full Text] [Related]
20. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
